August 2026 Electronic Mailbags
August 13, 2026
- Committee and Task Force Appointments
- DSCSA Exemptions from Certain Requirements Under Section 582 of the FD&C Act for Small Business Dispensers Until November 27, 2027
- Engagement of Compounding Strategy Advisors to Support Compounding Oversight
- Webinar on Peptide Regulation: Board Compliance Officers Are Invited to Attend
Committee and Task Force Appointments
Attached are the committee, task force, and work group appointments made by NABP President Nicki Chopski, PharmD, ANP.
NABP received an overwhelming response from members interested in volunteering for a committee or task force. President Chopski worked earnestly to involve as many people as possible, with a focus on appointing individuals who may be new to their state boards of pharmacy, new to NABP, or have not previously served on a committee or task force. The intent in this approach is to broaden participation in NABP and foster the involvement of new members in the Association.
DSCSA Exemptions from Certain Requirements Under Section 582 of the FD&C Act for Small Business Dispensers Until November 27, 2027
FDA DSCSA Exemptions for Small Dispensers
On August 6, 2026, the FDA announced it is granting exemptions from certain Drug Supply Chain Security Act (DSCSA) requirements under section 582 of the FD&C Act to small dispensers (e.g., pharmacies) and their applicable trading partners.
Key Dates:
- September 22, 2026 — Deadline for small dispensers to complete the small dispensers assessment survey
- November 27, 2026 — Cutoff date for determining eligibility as a “small dispenser” (companies with 25 or fewer full-time pharmacists/pharmacy technicians as of this date)
- November 27, 2027 — Exemption expiration date; small dispensers must comply with enhanced drug distribution security requirements by this deadline
Survey Request:
FDA is specifically encouraging small dispensers to complete the small dispensers assessment survey by September 22, 2026. Small dispensers may designate a third party (e.g., a consultant) to complete the survey on their behalf. The exemption period exists specifically to allow time to complete this assessment, publish the final report for public comment, and hold a public meeting on the results.
Other Notes:
- Small dispensers and trading partners using these exemptions do not need to notify or submit anything to FDA.
- Trading partners that don’t qualify for the exemption may request a waiver or exemption through CDER NextGen (CDER-regulated products) or via email for CBER-regulated products.
Engagement of Compounding Strategy Advisors to Support Compounding Oversight
The National Association of Boards of Pharmacy (NABP) is pleased to announce that it has engaged Compounding Strategy Advisors (CSA) to help shape and execute NABP’s compounding oversight strategy.
As compounding volumes continue to grow, so do the related oversight questions. In this environment, it is necessary for NABP to act quickly and provide boards with practical, well-grounded tools. CSA will provide support for this and brings deep 503A and 503B regulatory and compounding expertise through its advisors, Kathy Anderson, Ilisa Bernstein, and Gail Bormel.
CSA will assist NABP in three areas: oversight and inspection programs for outsourcing facilities, education and safety related to peptide compounding, and adverse event reporting and data sharing among states and with federal partners. As part of the peptide work, CSA will help NABP explore with the states the need for peptide compounding inspections.
CSA serves as a contracted expert advisor. NABP continues to set the strategy and direction of this work, and NABP’s focus remains what it has always been: protecting patient safety.
NABP will provide additional detail and answer questions during the 50-state executive officer call on August 21, 2026.
Webinar on Peptide Regulation: Board Compliance Officers Are Invited to Attend
NABP is pleased to expand the webinar audience to include compliance officers and investigators of the boards of pharmacy and colleges of pharmacists.
NABP is hosting a complimentary educational webinar for compliance officers, investigators, attorneys, and executive officers and registrars of the United States boards of pharmacy and Canada colleges of pharmacists, respectively: GLP-1 Medications, Peptides & the Evolving Regulatory Landscape. Webinar topics include the regulatory status of the peptide compounding by state-licensed pharmacies and outsourcing facilities. The webinar will take place on Thursday, October 8, 2026, at 1:00 PM Central Daylight Time.
In early September, NABP will send registration information for the webinar to the executive officers and registrars. We ask you to forward the registration information to the approved staff and attorneys who will attend the webinar.
If you have any questions, do not hesitate to email the Legal Affairs team at legalaffairs@nabp.pharmacy.
We sincerely look forward to you and your team joining us for the October webinar!